{
    "clinical_study": {
        "@rank": "23368", 
        "acronym": "MYME", 
        "arm_group": [
            {
                "arm_group_label": "arm A", 
                "arm_group_type": "Experimental", 
                "description": "Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.\n* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
            }, 
            {
                "arm_group_label": "arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "MULTICENTER, RANDOMIZED, COMPARATIVE STUDY OF MYOCET PLUS CYCLOPHOSPHAMIDE PLUS METFORMIN\n      VERSUS MYOCET PLUS CYCLOPHOSPHAMIDE IN FIRST LINE TREATMENT OF HER2 NEGATIVE METASTATIC\n      BREAST CANCER PATIENTS.\n\n      The aim of this study is to determine if the addition of metformin to the regime Myocet /\n      Cyclophosphamide improves disease-free survival in patients with HER2-negative metastatic\n      breast cancer.\n\n      The primary objective is the evaluation of the clinical efficacy of the combination of\n      Myocet / Cyclophosphamide plus Metformin compared to treatment with only Myocet /\n      Cyclophosphamide, in terms of progression-free survival (PFS).\n\n      Clinical secondary objectives are:\n\n        -  Objective response rate\n\n        -  Overall survival\n\n        -  Tolerability\n\n        -  Progression-free survival, objective response rate and overall survival according to\n           Homa Index levels.\n\n      Secondary biological endpoint is the characterization of the metabolic profile of patients\n      (sensitivity in insulin levels).\n\n      Treatment Arm A (experimental treatment):\n\n      Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1,\n      every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.\n\n      * During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin\n      chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a\n      day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.\n\n      Arm B (standard treatment):\n\n      Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2,\n      intravenous infusion, on day 1, every 21 days\n\n      Chemotherapy will be performed for 8 cycles.\n\n      The treatment will be continued until progression of disease.\n\n      Statistical Considerations:\n\n      In this randomized phase II study, the sample size was calculated basing on the primary\n      end-point (PFS) and assuming an error \u03b1 = 10% (2-tailed) with a power of 80%.\n\n      To find an advantage of 4 months of median time to progression (6 months in the control arm\n      B and 10 months in the experimental arm A) will be recruited 112 patients (98 events) for a\n      period of 24 months and will be considered further 12-month of follow-up. The primary\n      analysis of the study will be conducted in accordance with the \"intention to treat\"\n      principle, the secondary analysis will be conducted in the \"per protocol\" population."
        }, 
        "brief_title": "Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2-negative Metastatic Breast Cancer Patients", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have histologically or cytologically confirmed breast cancer\n\n          2. Metastatic disease\n\n          3. HER2 negative disease, as measured by IHC or FISH\n\n          4. Non endocrine responsive disease (negative hormonal status or failure of endocrine\n             therapy for MBC)\n\n          5. Patients with measurable and/or non-measurable disease according to RECIST Criteria\n             (Version 1.1)\n\n          6. Homa Index calculated according to Matthews' formula\n\n          7. Prior endocrine therapy is allowed, in the adjuvant and/or metastatic setting\n\n          8. Prior chemotherapy is allowed, only in adjuvant setting, provided it is terminated at\n             least 12 months before study entry. Adjuvant anthracyclines are allowed if prior\n             cumulative dose does not exceed 360 mg/m2 in case of epirubicin and 280 mg/m2 in case\n             of doxorubicin. Adjuvant taxanes are allowed.\n\n          9. Age 18-75 years\n\n         10. Life expectancy of greater than 3 months\n\n         11. ECOG performance status <2\n\n         12. Patients must have normal organ and marrow function:\n\n               -  leukocytes >=3,000/\u03bcL\n\n               -  absolute neutrophil count >=1,500/\u03bcL\n\n               -  platelets >=100,000/\u03bcL\n\n               -  total bilirubin within normal institutional limits\n\n               -  AST(SGOT)/ALT(SGPT) <=1.5 X institutional upper limit of normal\n\n               -  creatinine within normal institutional limits\n\n         13. Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF)>= 50%\n\n         14. The effects of liposomal doxorubicin on the developing human fetus at the recommended\n             therapeutic dose are unknown. For this reason and because anthracyclines as well as\n             other therapeutic agents used in this trial are known to be teratogenic, women of\n             child-bearing potential and men must agree to use adequate contraception (hormonal or\n             barrier method of birth control; abstinence) prior to study entry and for the\n             duration of study participation. All women of childbearing potential must have a\n             negative serum or urine pregnancy test within 72 hours prior to the start of study\n             medication. Should a woman become pregnant or suspect she is pregnant while\n             participating in this study, she should inform her treating physician immediately.\n\n         15. Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          1. Known diabetes (type 1 or 2)\n\n          2. Currently on metformin, sulfonylureas, thiazolidenediones or insulin for any reason\n             (these drugs alter insulin levels)\n\n          3. Current or previous congestive heart failure, renal failure or liver failure; history\n             of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day\n\n          4. Creatinine above upper limit of normal for institution, AST above 1.5 times upper\n             limit or normal for institution (to reduce risk of lactic acidosis)\n\n          5. Hypersensitivity or allergy to metformin\n\n          6. Participation in another clinical trial with any investigational agents within 30\n             days prior to study screening\n\n          7. Patients with known brain metastases should be excluded from this clinical trial\n             because of their poor prognosis and because they often develop progressive neurologic\n             dysfunction that would confound the evaluation of neurologic and other adverse events\n\n          8. History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to Myocet or other agents used in the study\n\n          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885013", 
            "org_study_id": "IRST174.04", 
            "secondary_id": "2009-014662-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "arm A", 
                "intervention_name": "Metformin + Myocet + Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "arm B", 
                "intervention_name": "Myocet + Cyclophosphamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 21, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Marina Faedi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cesena", 
                        "country": "Italy", 
                        "state": "FC"
                    }, 
                    "name": "P.O. M. Bufalini"
                }, 
                "investigator": {
                    "last_name": "Marina Faedi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "o.nanni@irst.emr.it", 
                    "last_name": "Oriana Nanni, PhD", 
                    "phone": "+39 0543739266"
                }, 
                "facility": {
                    "address": {
                        "city": "Meldola (FC)", 
                        "country": "Italy", 
                        "state": "FC", 
                        "zip": "47014"
                    }, 
                    "name": "Irccs Irst"
                }, 
                "investigator": {
                    "last_name": "Dino Amadori, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stefano Tamberi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Faenza", 
                        "country": "Italy", 
                        "state": "RA"
                    }, 
                    "name": "Ospedale Civile degli Infermi"
                }, 
                "investigator": {
                    "last_name": "Stefano Tamberi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giorgio Cruciani, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lugo", 
                        "country": "Italy", 
                        "state": "RA"
                    }, 
                    "name": "Ospedale Umberto I"
                }, 
                "investigator": {
                    "last_name": "Giorgio Cruciani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Giorgio Cruciani, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ravenna", 
                        "country": "Italy", 
                        "state": "RA"
                    }, 
                    "name": "Ospedale Civile Santa Maria delle Croci"
                }, 
                "investigator": {
                    "last_name": "Giorgio Cruciani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paolo Manente, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Asolo", 
                        "country": "Italy"
                    }, 
                    "name": "ULSS n.8 Asolo Ospedale di Castelfranco"
                }, 
                "investigator": {
                    "last_name": "Paolo Manente, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrea Freschi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy"
                    }, 
                    "name": "Centro di Riferimento Oncologico CRO"
                }, 
                "investigator": {
                    "last_name": "Andrea Freschi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Petros Giovanis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Belluno", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale S.Martino"
                }, 
                "investigator": {
                    "last_name": "Petros Giovanis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesco Carrozza, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Campobasso", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera \"Antonio Cardarelli\""
                }, 
                "investigator": {
                    "last_name": "Francesco Carrozza, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stefano Iacobelli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Chieti", 
                        "country": "Italy"
                    }, 
                    "name": "P.O. \"SS. Annunziata\""
                }, 
                "investigator": {
                    "last_name": "Stefano Iacobelli, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rosa Rita Silva, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Fabriano", 
                        "country": "Italy"
                    }, 
                    "name": "Presidio Ospedaliero E. Profili"
                }, 
                "investigator": {
                    "last_name": "Rosa Rita Silva, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alessandra Gennari, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "E.O. Galliera"
                }, 
                "investigator": {
                    "last_name": "Alessandra Gennari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Laura Scaltriti, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Guastalla", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale di Guastalla"
                }, 
                "investigator": {
                    "last_name": "Laura Scaltriti, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Aldo Iop, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Latisana", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda per i Servizi Sanitari n.5 \"Bassa Friulana\""
                }, 
                "investigator": {
                    "last_name": "Aldo Iop, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mariangela Ciccarese, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lecce", 
                        "country": "Italy"
                    }, 
                    "name": "Presidio Ospedaliero \"Vito Fazzi\""
                }, 
                "investigator": {
                    "last_name": "Mariangela Ciccarese, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mario Bari, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Mirano", 
                        "country": "Italy"
                    }, 
                    "name": "ULSS n.13 di Mirano"
                }, 
                "investigator": {
                    "last_name": "Mario Bari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Massimo Federico, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy"
                    }, 
                    "name": "Arcispedale S. Maria Nuova"
                }, 
                "investigator": {
                    "last_name": "Massimo Federico, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Virginia Casadei, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pesaro", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera S. Salvatore di Pesaro"
                }, 
                "investigator": {
                    "last_name": "Virginia Casadei, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Marco Lombardo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pescara", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale S. Spirito"
                }, 
                "investigator": {
                    "last_name": "Marco Lombardo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Luigi Cavanna, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Piacenza", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Civile di Piacenza"
                }, 
                "investigator": {
                    "last_name": "Luigi Cavanna, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Silvana Saracchini, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pordenone", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Santa Maria degli Angeli"
                }, 
                "investigator": {
                    "last_name": "Silvana Saracchini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Corrado Boni, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Reggio E,milia", 
                        "country": "Italy"
                    }, 
                    "name": "Arcispedale S. Maria Nuova"
                }, 
                "investigator": {
                    "last_name": "Corrado Boni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lorenzo Gianni, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rimini", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Civile degli Infermi"
                }, 
                "investigator": {
                    "last_name": "Lorenzo Gianni, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michele Aieta, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rionero in Vulture", 
                        "country": "Italy"
                    }, 
                    "name": "IRCCS Centro di riferimento Oncologico di Basilicata di Rionero in Vulture"
                }, 
                "investigator": {
                    "last_name": "Michele Aieta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Germano Zampa, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Nuovo Regina Margherita"
                }, 
                "investigator": {
                    "last_name": "Germano Zampa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "MYME: PHASE II COMPARATIVE STUDY OF MYOCET PLUS CYCLOPHOSPHAMIDE PLUS METFORMIN VERSUS MYOCET PLUS CYCLOPHOSPHAMIDE IN FIRST LINE TREATMENT OF HER2 NEGATIVE METASTATIC BREAST CANCER PATIENTS", 
        "overall_contact": {
            "email": "o.nanni@irst.emr.it", 
            "last_name": "Oriana Nanni, PhD", 
            "phone": "+390543739266"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical efficacy of the combination of Myocet / Cyclophosphamide plus Metformin compared to treatment with only Myocet / Cyclophosphamide, in terms of progression-free survival (PFS)", 
            "measure": "progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "42 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885013"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Objective Response Rate after treatment with Myocet/Cyclophosphamide/Metformin compared with after therapy with Myocet/Cyclophosphamide", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "description": "Overall survival after treatment with Myocet/Cyclophosphamide/Metformin compared with after therapy with Myocet/Cyclophosphamide", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "description": "Clinical efficacy of the combination of Myocet / Cyclophosphamide plus Metformin compared to treatment with only Myocet / Cyclophosphamide, in terms of progression-free survival (PFS) as function of Homa Index levels", 
                "measure": "Progression free survival as function of Homa Index levels", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "description": "Objective Response Rate after treatment with Myocet/Cyclophosphamide/Metformin compared with after therapy with Myocet/Cyclophosphamide, as function of Homa Index levels", 
                "measure": "objective response rate as function of Homa Index levels", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "description": "Overall survival after treatment with Myocet/Cyclophosphamide/Metformin compared with after therapy with Myocet/Cyclophosphamide, as function of Homa Index levels", 
                "measure": "overall survival as function of Homa Index levels", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }, 
            {
                "description": "Characterization of the metabolic profile of patients: sensitivity in insulin levels", 
                "measure": "patient metabolic profile (metabolic syndrome)", 
                "safety_issue": "No", 
                "time_frame": "42 months"
            }
        ], 
        "source": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}